申请人:HitGen Ltd.
公开号:US11149008B2
公开(公告)日:2021-10-19
The present invention discloses a compound shown in formula I or a stereoisomer, pharmaceutically acceptable salt, crystal form, solvate or isotopologue thereof. The compound of the present invention shows excellent inhibition activity against histone deacetylases, has remarkable inhibition effects on cancer cells, and provides a new choice of drugs used for the clinic treatment and diseases related to the abnormal activity of histone deacetylases.
本发明公开了一种式 I 所示的化合物或其立体异构体、药学上可接受的盐、晶型、溶液或异构体。本发明的化合物对组蛋白去乙酰化酶有很好的抑制活性,对癌细胞有显著的抑制作用,为临床治疗与组蛋白去乙酰化酶活性异常有关的疾病提供了新的药物选择。